1 of 1
Story summary
- Sanofi will acquire Dynavax Technologies for about $2.2 billion, at $15.50 per share, to bolster its vaccines business.
- The deal values Dynavax at a 39% premium over its recent close.
- Sanofi expects to close the acquisition in the first quarter of 2026, with no impact on its 2025 guidance.
- The announcement follows the Food and Drug Administration (FDA)'s rejection of Sanofi's experimental multiple sclerosis drug tolebrutinib.
